Marimed (MRMD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
The meeting was called to order by the President and CEO, who welcomed attendees and outlined the virtual format and agenda, emphasizing inclusivity and the order of business followed by a Q&A session.
Legal counsel, independent auditor, and board members were introduced, and meeting roles were assigned.
Board and executive committee updates
Directors present included the Chairman of the Board and three other board members.
The re-election of four directors to serve until the 2027 annual meeting was proposed and recommended by the board.
Overview of voting outcomes
A quorum was confirmed with over 50% of eligible votes present.
All director nominees were re-elected, and the appointment of the independent auditor for 2026 was approved.
Final voting results will be filed with the SEC within four business days.
Latest events from Marimed
- Q2 2026 revenue rose 6% to $41.9M, with strong retail, wholesale, and positive cash flow.MRMD
Q2 2026 - Revenue up 4.2% to $39.5M, adjusted EBITDA improved, and liquidity enhanced by restructuring.MRMD
Q1 2026 - Shareholders will vote on director elections and auditor approval, with robust governance and compensation disclosures.MRMD
Proxy filing - 2025 revenue rose 7% to $159.8M, driven by 11% wholesale growth and improved liquidity.MRMD
Q4 2025 - Four directors up for election, auditor approval, and key governance and compensation updates.MRMD
Proxy Filing - Q3 2024 revenue up 4.6% to $40.6M, net loss narrows, and wholesale outperforms.MRMD
Q3 2024 - Q2 revenue up 11% to $40.4M; margin pressure persists but 2024 growth targets reaffirmed.MRMD
Q2 2024 - Wholesale growth offset retail softness; Q2 revenue expected to rise high single digits QoQ.MRMD
Q1 2025 - Record revenue and wholesale gains offset margin pressure and retail softness in 2024.MRMD
Q4 2024